- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
1 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$767.76 | -2.7% | 34.6% | US$691.3b | US$984.05 | PE82.6x | E29.8% | 0.8% | ||
OSTX New | US$3.97 | 31.5% | n/a | US$84.3m | US$12.67 | PE-11.4x | E3.3% | n/a | ||
CDXC | US$5.49 | -10.3% | 278.6% | US$420.3m | US$7.96 | PE283x | E81.8% | n/a | ||
RGEN | US$144.46 | -7.6% | -20.9% | US$8.1b | US$191.46 | PS12.8x | E51.8% | n/a | ||
MLAB | US$132.08 | 3.5% | 25.7% | US$717.4m | US$133.33 | PS3.1x | E134.3% | 0.5% | ||
CSBR | US$7.51 | 18.6% | 49.8% | US$102.8m | US$8.00 | PS1.9x | E101.4% | n/a | ||
BLFS | US$27.39 | 2.6% | 70.9% | US$1.3b | US$30.20 | PS8.6x | E73.6% | n/a |
Page 1 of 1